Stifel analyst Bradley Canino reiterated a Hold rating and $5.00 price target on Affimed Therapeutics (NASDAQ: AFMD).The analyst commented, "New ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE